^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Pertuvia (pertuzumab biosimilar)

    i
    Other names: BCD-178, BCD 138, BCD-138
    Associations

    News

    Trials
    Company:
    Biocad
    Drug class:
    HER2 dimerization inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov)
    P2, N=6452, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Mekinist (trametinib) • Xalkori (crizotinib) • Tagrisso (osimertinib) • Gilotrif (afatinib) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • Vitrakvi (larotrectinib) • sunitinib • Kadcyla (ado-trastuzumab emtansine) • Balversa (erdafitinib) • Mektovi (binimetinib) • adavosertib (AZD1775) • Truqap (capivasertib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • sapanisertib (CB-228) • ipatasertib (RG7440) • taselisib (GDC-0032) • omipalisib (GSK2126458) • ulixertinib (BVD-523) • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Fakzynja (defactinib) • GSK2636771 • Paletan (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Pertuvia (pertuzumab biosimilar)
    4ms
    Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=315, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    carboplatin • docetaxel • Trazimera (trastuzumab-qyyp) • goserelin acetate • Paletan (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar)
    4ms
    PREFER: Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=398, Active, not recruiting, Biocad | Trial primary completion date: Jan 2024 --> Jun 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 expression
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • Pertuvia (pertuzumab biosimilar)
    9ms
    Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=315, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    carboplatin • docetaxel • Trazimera (trastuzumab-qyyp) • goserelin acetate • Paletan (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar)
    over1year
    NRG-BR004: Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=190, Active, not recruiting, National Cancer Institute (NCI) | N=600 --> 190 | Trial completion date: Apr 2024 --> May 2025
    Enrollment change • Trial completion date • Metastases
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • IL2 (Interleukin 2)
    |
    HER-2 positive
    |
    Tecentriq (atezolizumab) • paclitaxel • docetaxel • Trazimera (trastuzumab-qyyp) • Paletan (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar)
    over1year
    Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=315, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    carboplatin • docetaxel • Trazimera (trastuzumab-qyyp) • goserelin acetate • Paletan (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar)
    almost2years
    Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    Trazimera (trastuzumab-qyyp) • Paletan (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar)
    2years
    Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    Trazimera (trastuzumab-qyyp) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar)
    2years
    Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer (clinicaltrials.gov)
    P1/2, N=2, Terminated, National Cancer Institute (NCI) | N=12 --> 2 | Recruiting --> Terminated; Inadequate accrual rate
    Enrollment change • Trial termination • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    HR positive • PIK3CA mutation • PTEN mutation
    |
    Herceptin (trastuzumab) • Aliqopa (copanlisib) • Trazimera (trastuzumab-qyyp) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar)
    over2years
    PREFER: Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=336, Recruiting, Biocad
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 expression • PGR expression
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • Pertuvia (pertuzumab biosimilar)